Premium Mavacamten API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Mavacamten (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Cardiac Myosin Inhibitor

Indications: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Mavacamten distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Mavacamten is a first-in-class, orally bioavailable small-molecule Active Pharmaceutical Ingredient (API). In cardiovascular pharmacology, it represents a profound shift in the treatment of hypertrophic cardiomyopathy (HCM). For pharmaceutical manufacturers developing advanced cardiac portfolios, this API provides a disease-modifying approach rather than traditional symptom management.

At the physiological level, obstructive hypertrophic cardiomyopathy (oHCM) is characterized by hypercontractility of the left ventricle and impaired diastolic relaxation, leading to dynamic left ventricular outflow tract (LVOT) obstruction. This pathology is driven by genetic mutations in the cardiac sarcomere.

Mavacamten addresses this underlying defect directly. It functions as a selective, allosteric and reversible inhibitor of cardiac myosin. By modulating the number of myosin heads that can enter "on actin" (power-generating) states, the API effectively reduces the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. This targeted inhibition reduces excessive cardiac muscle contractility, thereby improving myocardial energetics, decreasing LVOT gradients, and restoring normal diastolic compliance.

For pharmaceutical formulation scientists, integrating this API allows for the development of highly specialized cardiovascular therapeutics. In commercial manufacturing, this active ingredient is typically formulated into low-dose hard gelatin capsules.

Sourcing Mavacamten in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced cardiovascular formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty cardiac APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing MAVACAMTEN Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard batch or are scaling up a high-volume MAVACAMTEN api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages or raw material shortages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during blending and encapsulation processes.

Technical Specifications for QA & R&D

The Mavacamten API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: 3-isopropyl-6-{[(1S)-1-phenylethyl]amino}pyrimidine-2,4(1H,3H)-dione
• CAS Number: 1642288-47-8
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C15H19N3O2
• Molecular Weight: 273.33 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Mavacamten is a highly potent cardiovascular compound capable of significantly reducing left ventricular ejection fraction. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor from accidental systemic exposure.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent degradation and maintain structural integrity.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or powered air-purifying respirators (PAPR), chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure containment isolators to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.